A practical Bayesian design to identify the maximum tolerated dose contour for drug combination trials

Drug combination therapy has become the mainstream approach to cancer treatment. One fundamental feature that makes combination trials different from single-agent trials is the existence of the maximum tolerated dose (MTD) contour, that is, multiple MTDs. As a result, unlike single-agent phase I trials, which aim to find a single MTD, it is often of interest to find the MTD contour for combination trials. We propose a new dose-finding design, the waterfall design, to find the MTD contour for drug combination trials. Taking the divide-and-conquer strategy, the waterfall design divides the task of finding the MTD contour into a sequence of one-dimensional dose-finding processes, known as subtrials. The subtrials are conducted sequentially in a certain order, such that the results of each subtrial will be used to inform the design of subsequent subtrials. Such information borrowing allows the waterfall design to explore the two-dimensional dose space efficiently using a limited sample size and decreases the chance of overdosing and underdosing patients. To accommodate the consideration that doses on the MTD contour may have very different efficacy or synergistic effects because of drug-drug interaction, we further extend our approach to a phase I/II design with the goal of finding the MTD with the highest efficacy. Simulation studies show that the waterfall design is safer and has higher probability of identifying the true MTD contour than some existing designs. The R package "BOIN" to implement the waterfall design is freely available from CRAN. Copyright © 2016 John Wiley & Sons, Ltd.

[1]  J O'Quigley,et al.  Continual reassessment method: a practical design for phase 1 clinical trials in cancer. , 1990, Biometrics.

[2]  Ying Yuan,et al.  Robust EM Continual Reassessment Method in Oncology Dose Finding , 2011, Journal of the American Statistical Association.

[3]  Ying Yuan,et al.  BAYESIAN PHASE I/II ADAPTIVELY RANDOMIZED ONCOLOGY TRIALS WITH COMBINED DRUGS. , 2011, The annals of applied statistics.

[4]  Anastasia Ivanova,et al.  Two‐Dimensional Dose Finding in Discrete Dose Space , 2005, Biometrics.

[5]  Ying Yuan,et al.  Bayesian dose finding in oncology for drug combinations by copula regression , 2009 .

[6]  Thomas M Braun,et al.  A Hierarchical Bayesian Design for Phase I Trials of Novel Combinations of Cancer Therapeutic Agents , 2010, Biometrics.

[7]  Ying Yuan,et al.  Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials , 2016, Clinical Cancer Research.

[8]  Adrian P Mander,et al.  A product of independent beta probabilities dose escalation design for dual-agent phase I trials , 2015, Statistics in medicine.

[9]  Ying Yuan,et al.  BAYESIAN DATA AUGMENTATION DOSE FINDING WITH CONTINUAL REASSESSMENT METHOD AND DELAYED TOXICITY. , 2013, The annals of applied statistics.

[10]  Ying Yuan,et al.  Bayesian dose finding by jointly modelling toxicity and efficacy as time‐to‐event outcomes , 2009 .

[11]  Ying Yuan,et al.  Sequential continual reassessment method for two‐dimensional dose finding , 2008, Statistics in medicine.

[12]  Shyamal D Peddada,et al.  Designs for Single‐ or Multiple‐Agent Phase I Trials , 2004, Biometrics.

[13]  John O'Quigley,et al.  Continual Reassessment Method for Partial Ordering , 2011, Biometrics.

[14]  Ying Yuan,et al.  Bayesian optimal interval designs for phase I clinical trials , 2015, Journal of the Royal Statistical Society: Series C (Applied Statistics).

[15]  Ying Yuan,et al.  A Bayesian dose finding design for oncology clinical trials of combinational biological agents , 2014, Journal of the Royal Statistical Society. Series C, Applied statistics.

[16]  Ying Yuan,et al.  A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents , 2009, Biometrics.

[17]  Ying Yuan,et al.  A Bayesian dose‐finding design for drug combination clinical trials based on the logistic model , 2014, Pharmaceutical statistics.

[18]  R. Dykstra,et al.  Isotonic Regression in Two Independent Variables , 1984 .

[19]  Ying Yuan,et al.  A Bayesian dose finding design for clinical trials combining a cytotoxic agent with a molecularly targeted agent , 2015 .

[20]  Thomas M Braun,et al.  A Generalized Continual Reassessment Method for Two-Agent Phase I Trials , 2013, Statistics in biopharmaceutical research.

[21]  Ying Yuan,et al.  Using Data Augmentation to Facilitate Conduct of Phase I–II Clinical Trials With Delayed Outcomes , 2014, Journal of the American Statistical Association.

[22]  Peter F Thall,et al.  Dose‐Finding with Two Agents in Phase I Oncology Trials , 2003, Biometrics.